At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
In Brief
A Phase 2 clinical trial evaluating Atezolizumab and Bevacizumab for Melanoma. Completed, enrolled 43 participants across 3 sites.
Detailed Summary
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartNov 2019
Primary CompletionAug 2022
Study CompletionSep 2023
TodayJul 2026
First PostedSep 16, 2019
Enrollment StartNov 25, 2019
Primary CompletionAug 31, 2022
Study CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.8 years ago
Interventions
Atezolizumabdrug
Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
Bevacizumabdrug
Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.